![]() |
|
|
Vol. 28, Issue 1, 1-4, January 2000
Center for Bioorganic 4-t-Butylcatechol (TBC) is an antioxidant used
primarily as a polymerization inhibitor for reactive monomers. Annual
production and use of TBC in the United States is approximately 1.5 million pounds. The absorption, tissue distribution, metabolism, and
excretion of [14C]TBC, labeled in the methine carbon, was
investigated in male Fischer 344 rats and B6C3F1 mice after
i.v., oral, and dermal administration. Oral (2 and 200 mg/kg in rats; 3 and 300 mg/kg in mice) and dermal (0.6, 6, and 63 mg/kg in rats; 1.3 and 157 mg/kg in mice) doses of TBC were well absorbed, then rapidly
metabolized and excreted primarily in urine. Dermal absorption of the
highest dose in the rat (87% of the 63 mg/kg dose) was significantly
higher than that of the two lower doses (0.6 and 6 mg/kg, 44 and 57%, respectively). Dermally administered TBC was also well absorbed in the
mouse (72-86%). Polar metabolites of TBC comprise all of the
radioactivity in the urine of both species after all routes of
administration. These were shown to consist mostly of the sulfate conjugates (and lesser amounts of the glucuronides) of TBC and of a
less polar metabolite. The deconjugated metabolite was isolated and
determined by mass spectrometry and 1H-NMR to be
mono-O-methylated TBC.
Chemistry,
Research Triangle
Institute,
Research Triangle Park,
North Carolina